How a payload is attached to an antibody determines how uniform - and how well-behaved - the resulting drug is. US12318457B2 - "Oligosaccharide linker, linker-payload comprising the same and glycan chain-remodeled antibody-drug conjugate," issued June 3, 2025 to GeneQuantum Healthcare (Suzhou) Co., Ltd. - claims attaching the payload through a remodeled glycan, at a defined site.

The load-bearing limitation is site-specific conjugation. Conventional conjugation attaches payloads at random surface residues (lysines or cysteines), producing a heterogeneous mixture with a variable drug-to-antibody ratio (DAR). The claimed method remodels the antibody's glycan - the sugar chain on its constant region - and attaches the payload there, at a controlled, defined site, yielding a homogeneous conjugate.

“The present disclosure further relates to a linker-payload compound including an oligosaccharide group, especially a disaccharide group, where the oligosaccharide group is linked to the remainder of the compound by an amide bond.”— U.S. Patent No. 12,318,457 source

The CPC profile is conjugation chemistry specific to this approach: A61K 47/6889 (linker classes), A61K 47/549 (the oligosaccharide linker), A61K 47/65, and the A61K 47/680xx payload-attachment series. The recurring glycan-and-linker tags mark this as a site-specific conjugation claim, distinct from random-attachment chemistries.

Why does site-specificity decide scope and value? Because a homogeneous, defined-DAR conjugate has a more predictable therapeutic window and cleaner pharmacology than a random mixture - a real clinical advantage. The claim reaches the glycan-remodeling conjugation method specifically; a competitor using cysteine-engineering or other site-specific approaches may fall outside a claim drawn to glycan-based attachment.

For the landscape, site-specific conjugation is one of the most actively contested corners of the ADC estate, with multiple incompatible approaches - glycan remodeling, engineered cysteines, enzymatic tagging - each separately patented. Freedom-to-operate for a next-generation ADC means choosing a conjugation approach and clearing the specific estate around it; GeneQuantum's glycan-remodeling grant defines one of those approaches.